Research & Clinical Trials

Retina Clinical Trials

Retina Center of Texas is dedicated to providing our patients with the most advanced retinal treatments and advancing the scientific understanding of retinal diseases.

The physicians are constantly evaluating developing medications for their potential impact on the retinal diseases that affect our patients. Every day new treatments are developed that could potentially cure blinding diseases. These medications undergo rigorous testing for efficacy and safety, and those few with the most potential make it to clinical trials. Testing at this stage requires centers that can diagnose, treat, and monitor diseases at the highest level. Bringing these treatments to our patients is an essential service at RCT.

To learn more about our current research protocols and activities, please continue reading about the trials offered below and contact our office at (817) 865-6800 for more information.

Macular Degeneration (Dry/GA)

Current Trials
IONIS

A Phase 2, Randomized, Placebo-Controlled, Double Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.

HORIZON

A Phase II, Open-Label, Outcomes-Assessor Masked, Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a single subretinal Injection in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration.

TELESCOPE

A Study to Genetically Define Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration.

CLOVER

A Decentralized Epidemiological Study of the Progression of Age-Related Macular Degeneration.

IVERIC

A Phase 3 Multicenter, Randomized, Double-Masked, Sham Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) In Patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.

Completed Trials
OPH2003

A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects with Geographic Atrophy secondary to Dry Age-Related Macular Degeneration.

Macular Degeneration (Wet)

Current Trials
ATMOSPHERE

A Randomized, Partially-Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.

UNITY-03

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active Controlled Study To Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 In Patients with Neovascular Age-Related Macular Degeneration.

AVONELLE

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration.

ASCENT

A Randomized, Partially Masked Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.

Completed Trials
PANDA

A Multicenter, Double Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy And Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration.

LUCERNE

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration.

OUTLOOK

A Clinical Effectiveness, Multicenter, Randomized, Double-Masked, Controlled Study of the Efficacy and Safety of ONE-5010 in Subjects with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.

OHR-1601

A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2%, Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.

Diabetic Macular Edema / Diabetic Retinopathy

Current Trials
ELEVATUM

A Phase IV, Multicenter, Open Label, Single Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment Naïve, Underrepresented Patients with Diabetic Macular Edema.

PAVILION

A Phase III, Multicenter, Randomized Study of the Efficacy, Safety and Pharmacokinetics Of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy.

ZETA-1

A Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy or Mild Proliferative Diabetic Retinopathy.

RHONE-X

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema.

OXURION NV

A Phase 2, Randomized, Multicenter study to assess the dose level of multiple.

THR-149

Injections and to evaluate the efficacy and safety of THR-149 versus Aflibercept for the treatment of diabetic macular edema.

Completed Trials
DRCR

Randomized Trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema.

KINGFISHER

A 12-month, 2-arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema.

RHINE

A Phase III, Multicenter, Randomized, Double-Masked, Active-comparator Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Diabetic Macular Edema.

Macular Telangiectasia

Current Trials
NHOR

A Natural History Observation and Registry Study of Macular Telangiectasia Type 2.

Completed Trials
NTMT

A Phase III, Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2.